On Thursday, 35 US states and the District of Colombia filed a lawsuit again the the opioid maker Indivior, alleging that the company tried to keep generic versions of a drug off the market.
Indivior makes Suboxone, a drug used to treat heroine addicts and addicts of other painkillers.
According to the lawsuit by the states, Indivior told the FDA that it planned to offer a new “sublingual film,” or dissolvable strip version of the drug, which had been licensed to Indivior by MonoSol.
Since the strip was not equivalent to the tablet version of the drug, it would prevent pharmacists from prescribing a cheaper generic alternative to patients.
The lawsuit claims that the company persuaded the FDA to approve the strip by raising concerns that the tablet posed high exposure risks to children. It later used those pediatric safety claims again to try to persuade the FDA not to approve generic tablets of Suboxone.
The complaint alleges that although the FDA rejected the company’s arguments, by the time the generics hit the marketplace, many patients had already switched over to using the dissolvable strip. There is currently no generic version of the dissolvable strip.
Full Content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI